Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012

Cancer Causes and Control

Volumn 26, Issue 8, 2015, Pages 1105-1116

  Baldur Felskov, Birgitte ^a   Munk, Christian ^a   Nielsen, Thor Schütt Svane ^a   Dehlendorff, Christian ^a   Kirschner, Benny ^b   Junge, Jette ^b   Kjaer, Susanne K ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

Adenocarcinoma in situ; Cervical cancer; CIN3; HPV; Incidence; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; AGE SPECIFIC INCIDENCE RATE; AGE STANDARDIZED INCIDENCE RATE; AGED; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER SCREENING; DENMARK; ESTIMATED ANNUAL PERCENTAGE CHANGE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REGISTER; TREND STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; YOUNG ADULT; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; UTERINE CERVICAL NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENMARK; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84937635261     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0603-7     Document Type: Article

References (52)

1. Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality WORLDWIDE: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed August 2014
2. Seoud M, Tjalma WA, Ronsse V (2011) Cervical adenocarcinoma: moving towards better prevention. Vaccine 29:9148–9158. doi:10.1016/j.vaccine.2011.09.115
3. Adegoke O, Kulasingam S, Virnig B (2012) Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 21:1031–1037. doi:10.1089/jwh.2011.3385
4. Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomark Prev 14:677–686
5. Kyndi M, Frederiksen K, Kruger KS (2006) Cervical cancer incidence in Denmark over six decades (1943–2002). Acta Obstet Gynecol Scand 85:106–111
6. Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E (2004) Increasing trends of cervical adenocarcinoma incidence in Central Italy despite extensive screening programme, 1985–2000. Cancer Detect Prev 28:461–464
7. Zhu C, Bassig BA, Zhang Y et al (2014) A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA. Eur J Cancer Prev. doi:10.1097/CEJ.0000000000000062
8. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A (2009) Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 20:1129–1138. doi:10.1007/s10552-009-9317-z
9. de Kok IM, van der Aa MA, van Ballegooijen M et al (2011) Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 128:2174–2181. doi:10.1002/ijc.25553
10. Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM (2007) Decreasing incidence of cervical adenocarcinoma in Ontario: this related to improved endocervical Pap test sampling? Int J Cancer 120:362–367
11. Sigurdsson K (1999) The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78:478–485
12. Lynge E (2002) Cervical cancer screening. Ugeskr Laeger 164:171–173
13. The Danish National Board of Health (2012) Screening for livmoderhalskræft–anbefalinger 2012 https://sundhedsstyrelsen.dk/publ/Publ2012/SYB/Kraeft/ScreenLivmoderhalskrftAnbef.pdf. Accessed October 2014
14. Stanley M (2010) Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117:S5–S10. doi:10.1016/j.ygyno.2010.01.024
15. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907
16. Moscicki AB, Schiffman M, Burchell A et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24–F33. doi:10.1016/j.vaccine.2012.05.089
17. Nøhr B, Frydshou D, Nielsen K, Fuglsang K, Hansen K, et al (2012) DSOG Kliniske Guidelines Udredning, behandling og kontrol af cervikal dysplasi (Danish Society of Obstetrics and Gynaecology). http://gynobsguideline.dk/hindsgavl/Cervixdysplasi2012.pdf. Accessed May 2014
18. Barken SS, Rebolj M, Andersen ES, Lynge E (2012) Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 130:2438–2444. doi:10.1002/ijc.26248
19. European Medicines Agency (2010) European public assessment report for Gardasil. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp. Accessed May 2014
20. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E (2012) Introduction of human papillomavirus vaccination in Nordic Countries. Vaccine 30:1425–1433. doi:10.1016/j.vaccine.2011.11.097
21. Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632
22. Castellsague X, Diaz M, de Sanjosé S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315
23. Pimenta JM, Galindo C, Jenkins D, Taylor SM (2013) Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 13:553. doi:10.1186/1471-2407-13-553
24. Garland SM, Smith JS (2010) Human papillomavirus vaccines: current status and future prospects. Drugs 70:1079–1098. doi:10.2165/10898580-000000000-00000
25. Kjaer SK, Munk C, Junge J, Iftner T (2014) Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 25:179–189. doi:10.1007/s10552-013-0320-z
26. Statens Serum Institut (2013) EPI-NYT: HPV-vaccination-tilslutning 2012. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2013/Uge%2020%20-%202013.aspx?p=1. Accessed May 2014
27. Statens Serums Institut (2014) Epi-nyt uge 47, Vaccinationstilslutning i det midlertidige HPV-vaccinationsprogram til kvinder født 1985–1992. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2014/Uge%2047%20-%202014.aspx. Accessed November 2014
28. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK (2014) Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:915–922. doi:10.1007/s10552-014-0392-4
29. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014) Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst 106: djt460. doi: 10.1093/jnci/djt460
30. Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39:42–45. doi:10.1177/1403494810393562
31. The Danish Pathology Data Bank (2011). http://www.patobank.dk/. Accessed May 2014
32. Statens Serum Institut (2013) Indberetning og patientregistrering: Patologi. http://www.ssi.dk/Sundhedsdataogit/Indberetning%20og%20patientregistrering/SEI/Patologi.aspx. Accessed November 2013
33. Dugue PA, Lynge E, Bjerregaard B, Rebolj M (2012) Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 54:266–269. doi:10.1016/j.ypmed.2012.01.012
34. Danske Regioner (2012) Økonomisk vejledning 2008, 2010, 2011 and 2012. http://www.regioner.dk/økonomi/økonomisk+vejledning/baggrundsmappe2007og2008/regionernes+bidrag+til+patobanken+i+2008. Accessed November 2013
35. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M (2001) Age standardization of rates: A new WHO standard. http://www.who.int/healthinfo/paper31.pdf. Accessed May 2013
36. R Development Core Team (2012) R: A language and environment for statistical computing. Auckland: R Foundation for Statistical Computing. Vienna, Austria. http://www.R-project.org. Accessed October 2013
37. Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F (2014) 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111:965–969. doi:10.1038/bjc.2014.362
38. Fujiwara K, Monk B, Devouassoux-Shisheboran M (2014) Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep 16:416. doi:10.1007/s11912-014-0416-y
39. Nygard M, Hansen BT, Dillner J et al (2014) Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 9:e88323. doi:10.1371/journal.pone.0088323
40. Foley G, Alston R, Geraci M, Brabin L, Kitchener H, Birch J (2011) Increasing rates of cervical cancer in young women in England: an analysis of national data 1982–2006. Br J Cancer 105:177–184. doi:10.1038/bjc.2011.196
41. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044
42. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB (2012) Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health 12:992. doi:10.1186/1471-2458-12-992
43. Dillner J (2000) Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 19:7–23
44. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F (2013) Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 49:3262–3273. doi:10.1016/j.ejca.2013.04.024
45. Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14:2191–2199
46. Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C (2013) Outcomes in cervical screening using various cytology technologies: what’s age got to do with it? Eur J Cancer Prev 22:367–373. doi:10.1097/CEJ.0b013e328359cbe0
47. Rask J, Lynge E, Franzmann M et al (2014) Impact of technology on cytology outcome in cervical cancer screening of young and older women. Int J Cancer 134:2168–2179. doi:10.1002/ijc.28532
48. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111:167–177. doi:10.1097/01.AOG.0000296488.85807.b3
49. Katki HA, Kinney WK, Fetterman B et al (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12:663–672. doi:10.1016/S1470-2045(11)70145-0
50. Nielsen SL, Daugbjerg SB, Gimbel H, Settnes A (2011) Use of vaginal hysterectomy in Denmark: rates, indications and patient characteristics. Acta Obstet Gynecol Scand 90:978–984. doi:10.1111/j.1600-0412.2011.01199.x
51. Domingo S, Pellicer A (2009) Overview of current trends in hysterectomy. Expert Rev Obstet Gynecol 4 (6): 673–85. doi:10.1586/eog.09.51. http://www.medscape.com/viewarticle/712569. Accessed August 2014
52. Lam JU, Lynge E, Njor SH, Rebolj M (2015) Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol Mar 24:1–8. doi:10.3109/0284186X.2015.1016625